Biogen (BIIB) Cash & Current Investments (2009 - 2026)

Biogen (BIIB) has reported Cash & Current Investments for 18 consecutive years, with $4.3 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 64.83% year-over-year to $4.3 billion; the TTM figure through Mar 2026 stood at $4.3 billion (up 64.83% YoY), while the FY2025 annual figure was $3.8 billion, up 60.66% from the prior year.
• Cash & Current Investments came in at $4.3 billion for Q1 2026 at Biogen, up from $3.8 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $6.1 billion in Q2 2023, with the low at $1.0 billion in Q4 2023.
• Average Cash & Current Investments over 5 years is $3.4 billion, with a median of $3.8 billion recorded in 2022.
• Across the five-year window, Cash & Current Investments sank 78.69% in 2024 and soared 141.84% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $4.9 billion in 2022, then sank by 78.54% to $1.0 billion in 2023, then jumped by 126.21% to $2.4 billion in 2024, then soared by 60.66% to $3.8 billion in 2025, then climbed by 12.24% to $4.3 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $4.3 billion, $3.8 billion, and $4.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.